Druggable cavities and allosteric modulators of the cell division cycle 7 (CDC7) kinase.
Elisa Rojas-PratsLoreto Martínez-GonzálezCarmen GilDavid RamírezAna MartinezPublished in: Journal of enzyme inhibition and medicinal chemistry (2024)
Cell division cycle 7 kinase (CDC7) has been found overexpressed in many cancer cell lines being also one of the kinases involved in the nuclear protein TDP-43 phosphorylation in vivo . Thus, inhibitors of CDC7 are emerging drug candidates for the treatment of oncological and neurodegenerative unmet diseases. All the known CDC7 inhibitors are ATP-competitives, lacking of selectivity enough for success in clinical trials. As allosteric sites are less conserved among kinase proteins, discovery of allosteric modulators of CDC7 is a great challenge and opportunity in this field.Using different computational approaches, we have here identified new druggable cavities on the human CDC7 structure and subsequently selective CDC7 inhibitors with allosteric modulation mainly targeting the pockets where the interaction between this kinase and its activator DBF4 takes place.
Keyphrases
- small molecule
- cell cycle
- protein kinase
- clinical trial
- protein protein
- tyrosine kinase
- endothelial cells
- prostate cancer
- cell proliferation
- cell therapy
- randomized controlled trial
- transcription factor
- squamous cell carcinoma
- emergency department
- high throughput
- radical prostatectomy
- rectal cancer
- combination therapy
- minimally invasive
- bone marrow
- inflammatory response
- smoking cessation
- papillary thyroid
- squamous cell
- lymph node metastasis